Pfizer blends modality tools in new vision for oncology unit
Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen
It’s a pivotal time for Pfizer’s oncology business, as the pharma aims to reverse declining revenues while integrating Seagen and its antibody-drug conjugate foundation. The acquisition nearly doubled the size of Pfizer’s clinical oncology pipeline and immediately added multiple blockbusters to the portfolio, but it’s the marriage of Pfizer’s legacy small molecule medicinal chemistry expertise and Seagen’s antibody engineering capabilities that will help define the longer-term strategy.
Pfizer Inc. (NYSE:PFE) kicked off 2024 with an oncology pipeline clustered around two core modalities: small molecules and antibody-drug conjugates. The split focus on two modalities is a departure from its historic pipeline strategy centered primarily on small molecules. ...